Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367546 | 0.95 | GPR119 (0.57) | GPR119HPGDRECQLEPHX1NR1H2 | |
| SCHEMBL17656738 | 0.92 | GPR119 (0.47) | GPR119HPGDNR1H2MAPTPRMT5 | |
| SCHEMBL15000982 | 0.92 | GPR119 (0.47) | GPR119HPGDNR1H2MAPTPRMT5 | |
| SCHEMBL14497234 | 0.92 | GPR119 (0.50) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL4097772 | 0.90 | GPR119 (0.60) | GPR119HPGDRECQLEPHX1NR1H2 | |
| SCHEMBL31540008 | 0.88 | GPR119 (0.47) | GPR119NR1H2 | |
| SCHEMBL31540076 | 0.88 | GPR119 (0.47) | GPR119NR1H2 | |
| SCHEMBL13748769 | 0.88 | NR1H2 (0.50) | GPR119NR1H2MAPTPRMT5WDR77 | |
| SCHEMBL25974405 | 0.88 | GPR119 (0.53) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL20303147 | 0.87 | GPR119 (0.58) | GPR119HPGDRECQLEPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-115232108-B | SOS1 degradation agent and preparation method and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4519273-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2024263586-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240247000-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2024-07-25 | — | — | US | disclosed |
| CN-115232114-B | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | GPR119 2659/4885HPGD 3048/4885RECQL 1077/4885 |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | KRAS, NRAS, HRAS | GPR119 2659/4885HPGD 3048/4885RECQL 1077/4885 |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | GPR119 3494/4885HPGD 3600/4885RECQL 1329/4885 |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RAC1, SOS1, RSU1 | GPR119 3124/4885HPGD 2612/4885RECQL 1447/4885 |
| US-20240247000-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | GPR119 2659/4885HPGD 3048/4885RECQL 1077/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | GPR119 165/4885HPGD 262/4885RECQL 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.